Nymox Pharmaceutical Release: BPH: A Major Challenge for Men’s Healthcare

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has developed an innovative new treatment for BPH, NX-1207, which has now entered Phase 3, the final stage of drug testing before applying for FDA approval.